Paxlovid 150 mg, 100 mg Tablet
PDF Leaflet Revision Date: 01 January 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of COVID-19 in adults at risk for severe disease.
Dosage (summary)
300 mg nirmatrelvir + 100 mg ritonavir, orally twice daily for 5 days.
Onset of Action / Duration
Onset: Within 5 days of symptom onset, Duration: 5 days.
Special Populations
- Elderly: No dose adjustment needed.
- Renal impairment: Adjust dose in moderate impairment.
- Hepatic impairment: Contraindicated in severe impairment.
Pregnancy & Breastfeeding
Not recommended during pregnancy; breastfeeding should be discontinued during treatment.
Key Drug Interactions
- Contraindicated with CYP3A substrates (e.g., alfuzosin, pethidine).
- Increases plasma concentrations of CYP3A substrates.
Contraindications
- Severe hepatic impairment.
- Severe renal impairment.
- Hypersensitivity to components.
Common side effects
- Diarrhoea
- Vomiting
- Dysgeusia
Counselling Points
- Take with or without food.
- Do not chew or crush tablets.
- Monitor for adverse reactions.
Serious warnings
- Risk of serious drug interactions.
- Potential for hepatotoxicity.
Important Disclaimer
The Paxlovid 150 mg, 100 mg Tablet professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
